

June 16, 2016

Dear Shareholders

Christophe Weber
President and Representative Director
Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome
Chuo-ku, Osaka

Partial Correction to the Business Report attached to the Notice of Convocation of the
140th Ordinary General Meeting of Shareholders

Takeda Pharmaceutical Company Limited (the “Company”) hereby reports that there are parts to be corrected in the Business Report attached to the Notice of Convocation of the 140th Ordinary General Meeting of Shareholders that was sent on June 7, 2016 (the “Notice”) and that the Company therefore decided to make corrections to the said parts as described herein below.

1. Correction parts:

Item 3 of the Business Report “Matters Concerning the Stock Acquisition Rights of the Company” set forth on page 75 of the Notice

2. Contents of the correction:

[After correction]

(Underlined sections indicate changes)

Name (Date of resolution for issuance)	Type and number of shares subject to Stock Acquisition Rights (and the number of Stock Acquisition Rights)
2 nd Series of Stock Acquisition Rights FY2011- issued (June 24, 2011)	Ordinary shares in the Company; <u>1,208,300 shares (12,083)</u>
2 nd Series of Stock Acquisition Rights FY2012- issued (July 30, 2012)	Ordinary shares in the Company; <u>1,764,300 shares (17,643)</u>

[Before correction]

(Underlined sections indicate changes)

Name (Date of resolution for issuance)	Type and number of shares subject to Stock Acquisition Rights (and the number of Stock Acquisition Rights)
2 nd Series of Stock Acquisition Rights FY2011- issued (June 24, 2011)	Ordinary shares in the Company; <u>1,209,300 shares (12,093)</u>
2 nd Series of Stock Acquisition Rights FY2012- issued (July 30, 2012)	Ordinary shares in the Company; <u>1,806,600 shares (18,066)</u>

[End of document]